Arban Domi, Ph.D., has been appointed director of Vector Development at GeoVax Labs, Inc. Dr. Domi will play a key role in the continued development of GeoVax’s HIV vaccines currently in clinical trials, as well as the development of vaccines for HIV subtypes affecting the developing world. Dr. Domi will also be instrumental in the company’s evaluation of vaccine constructs for commercial-scale vaccine manufacturing processes.
 
From 2000 to 2008, Dr. Domi was a Research Fellow in the Laboratory of GeoVax collaborator, Dr. Bernard Moss, at the U.S. National Institutes of Health, where he worked on poxviruses, viral vectors and recombinant virus construction, as well as the replication and egress of vaccinia virus. Dr. Domi was the co-inventor of the first infectious clone of a poxvirus cloned in bacteria and he developed a new expression system, VAC-BAC shuttle vector system for construction of recombinant poxviruses in E. Coli. In 2008 he joined the International AIDS Vaccine Initiative (IAVI) laboratory in Brooklyn, NY, as a Principal Scientist and since 2011, has served as head of Process Development and Virus Production at IAVI.
 
“We are very pleased that Dr. Domi will be joining us,” said Harriet Robinson, GeoVax’s chief scientific officer. “Arban’s expertise in working with vaccinia virus and constructing recombinant viruses, as well as his experience as a Principal Scientist at the International AIDS Vaccine Initiative, will greatly add to our scientific talent at GeoVax. We are fortunate that our vaccine program could attract a professional of Dr. Domi’s caliber, and we look forward to his contributions.”